Loading
A phase 2 trial of Pembrolizumab, Belzutifan and Lenvatinib in advanced solid tumours, run by Merck Sharp & Dohme LLC, active and no longer recruiting.
Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016) is a phase 2 interventional study registered as NCT04976634 by Merck Sharp & Dohme LLC, with 730 participants enrolled, started 2021-08-18 and due to reach its primary completion in 2027-03-22. Interventions recorded: Pembrolizumab, Belzutifan and Lenvatinib.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Belzutifan, Lenvatinib, Anti-angiogenic therapy, Merck & Co. (MSD) and the tag pipeline.
Shares Belzutifan, Lenvatinib, Merck & Co. (MSD), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Belzutifan, Lenvatinib, Merck & Co. (MSD), Pembrolizumab and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/